Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2021—nRichDX launched its Revolution Semi-Automated Workflow powered by Eppendorf’s epMotion 5073 instrument for the extraction of cfDNA and ctDNA from plasma and urine for liquid-based assay development. The semiautomated workflow automates the Revolution protocol’s wash and elution steps and is designed to increase yield, sensitivity, and throughput.
April 2021—The Center for Phlebotomy Education has released a training video from its Applied Phlebotomy series that can be streamed online through the Phlebotomy Channel.
April 2021—Bio-Rad Laboratories has enhanced its InteliQ liquid quality controls product line. InteliQ products have improved open-vial stability, and they are now available on Abbott Alinity and Roche Cobas systems.
April 2021—Diazyme received FDA emergency use authorization for its Semi-Quantitative DZ-Lite SARS-CoV-2 IgG CLIA test, which runs on the DZ-Lite 3000 Plus chemiluminescence analyzer. The FDA granted Diazyme an EUA for its qualitative DZ-Lite SARS-CoV-2 IgG CLIA test in July and has now authorized the Diazyme IgG assay to be used as a semiquantitative test.
April 2021—Qiagen launched its QIAsphere cloud-based platform, which will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week.
April 2021—Bio-Rad Laboratories announced that its Reliance SARS-CoV-2/FluA/FluB RT-PCR and Reliance SARS-CoV-2 RT-PCR assay kits were granted emergency use authorization by the FDA.
April 2021—Bio SB has developed a new panel of SARS-CoV-2 antibodies to identify the COVID-19 virus, its receptors, and its cytokines by immunohistochemistry and immunofluorescence on formalin-fixed, paraffin-embedded biopsies. The antibodies identify ACE2, CD147, and TMPRSS2 receptors and include markers for immune response factors and vascular cells, with the intention to assess the pathological damage caused by COVID-19, cytokine storm syndrome, and coagulopathy, using single and multiplex IHC and immunofluorescence on FFPE tissues.
April 2021—Sarstedt introduced its dedicated transportation system for sending specimen tubes to the laboratory, the Tempus600. Sample tubes are placed directly into a sending station and arrive within seconds at a laboratory receiving station for processing. An optional connection module enables tubes to be loaded directly into laboratory automation systems, such as the Sarstedt BL 1200 bulk loader and sorter. The Tempus600 system and pipelines require little space, and installation takes two weeks.
April 2021—PerkinElmer announced that its PerkinElmer New Coronavirus Nucleic Acid Detection Kit received emergency use authorization from the FDA to test individuals without symptoms or other reasons to suspect COVID-19 infection.
April 2021—Cue Health has received FDA emergency use authorization for over-the-counter sale of its COVID-19 test. The Cue COVID-19 Test for Home and Over the Counter Use uses a lower nasal swab and provides results in about 20 minutes. The Cue OTC test is authorized for use by symptomatic and asymptomatic individuals, ages two and older.
